Immunic (IMUX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov14

H.C. Wainwright Reiterates Buy Rating on Immunic with a Price Target of $8.00

11:42

Immunic released FY2025 9 Months Earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -0.5861

04:00

Immunic released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1319 (forecast USD -0.19)

04:00

Oct27

Matthew Caufield Gives Buy Rating to Immunic's Vidofludimus Calcium

10:32

Sep25

Immunic Presents Clinical Data of Vimizim for Multiple Sclerosis Treatment

10:31

Aug8

Immunic released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.4475

03:00

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -25.58 M, EPS -0.1319

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -26.82 M, EPS -0.2718

May15

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -25.47 M, EPS -0.2825

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change